UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023.

Commission File Number: 001-40627

SOPHiA GENETICS SA
(Exact name of registrant as specified in its charter)

Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHIA GENETICS SA

Date: June 6, 2023

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer
<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Presentation SOPHiA GENETICS at William Blair's Annual Growth Conference dated June 6, 2023</td>
</tr>
</tbody>
</table>
Democratizing Data-Driven Medicine

Dr. Jurgi CAMBLONG
Chief Executive Officer & Co-Founder

June 6, 2023
Cautionary Notices

This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this presentation. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this presentation to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

No offer to sell or buy

This presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Other material information

This presentation does not contain all material information about SOPHIA GENETICS SA and its subsidiaries. No representations or warranties (expressed or implied) are made regarding the completeness of the information contained in this presentation. Refer to our Securities and Exchange Commission filings for additional information about us.

Market and industry data

This presentation contains industry, market and competitive position data that are based on general and industry publications, surveys and studies conducted by third parties, some of which may not be publicly available, and our own internal estimates and research. Our estimates of addressable market (or similar concepts) are primarily based on epidemiological data, including incidence and prevalence estimates of addressable populations, as well as a range of price assumptions for our products taking into account differences in panel sizes, which may change over time. Third-party publications, surveys and studies generally state that they have obtained information from sources believed to be reliable, but do not guarantee the accuracy and completeness of such information. While we are not aware of any misstatements regarding the industry, market and competitive position data presented herein, these data involve a number of assumptions and limitations and contain projections and estimates of the future performance of the industries in which we operate that are subject to a high degree of uncertainty.

Research use only

SOPHIA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this presentation is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Snapshot of SOPHiA Genetics

We are a category defining software company on a mission to Democratize Data-Driven Medicine.

The information on this slide is as of 05/30/2023.
The Emergence of the Cloud and AI have transformed countless of industries.

BUT, Healthcare is lagging.
# Healthcare Data is Complex, Siloed and Diverse

## Clinical
- Symptoms: Coughing, Shortness of breath, Tiredness
- Medical history: Family history, Smoking history, Performance status
- Treatment decisions
- Quality of life

## Imaging
- Chest X-ray
- CT scan
- MR scan
- PET/CT scan
- Image-guided biopsy

## Histopathology
- PD-L1
- M0E

## Genomics
- NGS
- NGS with MSI
- NGS with MAP

## Lab tests
- Complete blood count (CBC)
- Blood count (BC)
- Tumour marker assay (TM)
- Clinical chemistry (CC)
- 2ND line treatment
Creating Network Effects in Healthcare is Difficult
given non-standardized methods and sensitive data
Significantly Important for Key Diseases

driven by genomic alterations

Cancer
>25 Million New Cancer Cases per Year\(^1\)

Rare Diseases
~5% of the global population suffers from a Rare Disease\(^2\)

1. by 2040; 2. https://www.rarediseasesinternational.org/
New Data Modalities Bring Objectivity into human biology and diseases.
Applying AI to Genomic Data

HRD example for PARP inhibitors

Low-pass WGS coverage → Feature extraction → Classifier → Output

- Low-pass WGS coverage: High-dimensional data
- Feature extraction: Convolutional neural network
- Classifier: Neural network
- Output: SOPHiA GENETICS Genomic Integrity Index (GI)
Our Ability to Deliver Healthcare Solutions
Built on collective intelligence from our global network

**Deployment**
Expand access to genomic applications (both internal or 3rd party) by leveraging our global network

**Discovery**
Apply benefits of proprietary AI/ML to late-stage discovery phases

**Development**
Comprehensive suite of applications backed by AI-based algorithms to aid in harmonization and reporting
Transforming Healthcare through Key Strategic Collaborations

- Generate robust insights
- Break data silos
- Create a collective intelligence
- Accelerate adoption of precision medicine
Growing with our Customer’s Volume
via a consumption based SaaS model

Upload Data

Proprietary Algorithms and patented technologies

MNA, SINGER, PEPPER

Proprietary Algorithms and patented technologies

BUSTAT, CLUMIN, MUSTARD

Contribution based model

$ Interpret Data

Targeted Clinical Outcomes

University Hospitals

Comprehensive Cancer Centers

Specialty Labs

Central Labs

In-House Sequencing

Clinical Reporting

© SOPHIA GENETICS 2023

FN 1: Patents pending.
A Look into a Customer’s Expansion Journey
as volume and the number of applications increase

JAN 2019
- $8K revenue
- 5 applications
- 200 analyses

END 2019
- $160K revenue
- 7 applications
- 3,900 analyses

END 2020
- $270K revenue
- 7 applications
- 3,200 analyses

END 2021
- $650K revenue
- 9 applications
- 6,100 analyses

2022
- $1.1M revenue
- 9 applications
- 9,900 analyses

Since 2019
91% Revenue CAGR
47% analysis CAGR
100% of somatic business converted

Successful partnership founded on collaboration, loyalty, and trust
Importantly, Customer Growth Accelerates as they get Larger

Total Revenue Growth CAGR by Grouped Tier

2019
22
9
23
22
246

2022
51
13
24
37
265

Customer count by annual revenue contribution

$200K+
$150K-200K
$100K-150K
$50-100K
< $50K+

Note: Based on recurring platform customers. FN 1: Represents CAGR of total tier revenue of customers with $100K+ in revenue and CAGR of total tier revenue of customers with $50-$100K in revenue.
© SOPHiA GENETICS 2023
Key Financial Metrics

750+
Total customers \(^{(1)}\)

430+
Core Genomics customers \(^{(1)}\)

1.3 million+
Genomic Profiles Analyzed \(^{(5)}\)

~77,000+
Genomic profiles analyzed in 1Q 2023 \(^{(1)}\)

30% - 35%
2023 constant currency ex COVID revenue growth guidance as of May 9, 2023 \(^{(2,4)}\)

37%
1Q2023 constant currency ex COVID revenue growth \(^{(3)}\)

69% | 73%
Q1 2023 IFRS gross profit margin | adjusted gross profit margin \(^{(5)}\)

~$162M
Cash, cash equivalents, & term deposits \(^{(2)}\)

FN 1: Represents statistic as of 03/31/2023. FN 2: The Company is unable to provide a reconciliation of forward-looking constant currency revenue growth excluding COVID-19-related revenue to Revenue, the most comparable IFRS financial measure, due to the inherent difficulty in forecasting and quantifying the impact of foreign currency translation. FN 3: Please refer to appendix for non-IFRS reconciliation. FN 4: Represents financial outlook as of May 9, 2023. This presentation does not represent an update or affirmation of previously disclosed guidance. FN 5: Represents statistic as of 05/30/2023.
Thank You
Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin
for the Three Months Ended March 31, 2023

<table>
<thead>
<tr>
<th>Amounts in USD thousands</th>
<th>Three months ended March 31, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$13,966</td>
</tr>
<tr>
<td>Cost of revenue</td>
<td>(4,272)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$9,694</td>
</tr>
<tr>
<td>Amortization of capitalized research and development expenses (1)</td>
<td>432</td>
</tr>
<tr>
<td>Adjusted gross profit</td>
<td>$10,126</td>
</tr>
<tr>
<td>Gross profit margin</td>
<td>60%</td>
</tr>
<tr>
<td>Amortization of capitalized research and development expenses (1)</td>
<td>4%</td>
</tr>
<tr>
<td>Adjusted gross profit margin</td>
<td>73%</td>
</tr>
</tbody>
</table>
# Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth and Constant Currency Revenue Growth Excluding COVID-19-Related Revenue

(Amounts in USD thousands)

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Reported Revenue</strong></td>
<td>$10,861</td>
<td>$13,966</td>
</tr>
<tr>
<td><strong>Y-o-Y Growth</strong></td>
<td>21%</td>
<td>29%</td>
</tr>
<tr>
<td><strong>Current Period Constant Currency Impact</strong></td>
<td></td>
<td>618</td>
</tr>
<tr>
<td><strong>Constant Currency Revenue</strong></td>
<td>$10,861</td>
<td>$14,584</td>
</tr>
<tr>
<td><strong>Y-o-Y Growth</strong></td>
<td></td>
<td>34%</td>
</tr>
<tr>
<td><strong>COVID-19 Revenue</strong></td>
<td>(331)</td>
<td>(125)</td>
</tr>
<tr>
<td><strong>Constant Currency Impact on COVID-19 Revenue</strong></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td><strong>Constant Current Revenue Excluding COVID-19 Revenue</strong></td>
<td>$10,530</td>
<td>$14,464</td>
</tr>
<tr>
<td><strong>Y-o-Y Growth</strong></td>
<td></td>
<td>37%</td>
</tr>
</tbody>
</table>
Notes to the Reconciliation of IFRS to Adjusted Financials

(1) Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives.
Consistent Growth in Analysis Volume

accelerated momentum of analysis volume conducted on our platform going into 2023

Includes analysis volume from all Core Genomics Customers using dry lab, bundle access, and integrated access models.